Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) announced that the company recently received a Drug Registration Certificate from the National Medical Products Administration for its Class 1 innovative drug Anrukefen Injection (brand name: Sisujing®, development code: HSK21542). The newly approved indication is for "the treatment of moderate to severe pruritus associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments